Childhood bladder carcinoma

Summary

Childhood bladder carcinoma (MONDO:0022578) is a cancer and 1,230 clinical trials. Top therapeutic interventions include mitomycin, fluorouracil, and sunitinib. A subtype of urinary bladder carcinoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Classification: Cancer
• Clinical trials: 1,230

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	childhood bladder carcinoma
Mondo ID	MONDO:0022578
NCIT	C118816
UMLS	C3899675
MedGen	859269
GARD	0027906
Is cancer (heuristic)	yes

Also known as: bladder cancer · bladder cancer childhood · bladder cancer, childhood · bladder carcinoma, childhood · childhood bladder cancer · childhood bladder carcinoma

Disease family

This is a subtype of urinary bladder carcinoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › urinary system disorder › urinary bladder disorder › urinary bladder neoplasm › urinary bladder cancer › urinary bladder carcinoma › childhood bladder carcinoma

Related subtypes (8): bladder adenocarcinoma, bladder squamous cell carcinoma, bladder urachal carcinoma, urinary bladder small cell neuroendocrine carcinoma, stage IVb bladder cancer, superficial urinary bladder carcinoma, bladder transitional cell carcinoma, bladder small cell carcinoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 1,230.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	451
PHASE2	286
PHASE1	132
PHASE3	106
PHASE1/PHASE2	81
PHASE4	18
PHASE2/PHASE3	13
EARLY_PHASE1	13

Top trials by phase / activity

NCT	Phase	Status	Title
NCT04532606	PHASE4	RECRUITING	Impact of Remimazolam on Prognosis After Bladder Cancer Surgery
NCT06548438	PHASE4	NOT_YET_RECRUITING	The Impact of PDD During TURB for NMIBC
NCT06764095	PHASE4	RECRUITING	Enfortumab Vedotin and Pembrolizumab With Cystectomy and/or Ureterectomy for Locally Advanced or Metastatic Bladder and Upper Urothelial Tract Cancer, CAST-AI Trial
NCT00365508	PHASE4	COMPLETED	Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking
NCT00666978	PHASE4	COMPLETED	Health Education Counseling With or Without Bupropion in Helping African Americans Stop Smoking
NCT00785694	PHASE4	WITHDRAWN	Recurrence of Bladder Cancer After Transurethral Resection With Hexvix
NCT02001857	PHASE4	COMPLETED	Effect of TachoSil® on Incidence of Symptomatic and Radiographic Lymphoceles After Extended Pelvic Lymph Node Dissection in Prostate and Bladder Cancer.
NCT02443844	PHASE4	UNKNOWN	Comparison of Medical and Surgical Treatments of Benign Prostate Hyperplasia in Patients Who Have Low Grade Non Muscle Invasive Bladder Cancer for Tumour Recurrence and Progression
NCT03138967	PHASE4	COMPLETED	Investigation of Sugammadex in Outpatient Urological Procedures
NCT03147586	PHASE4	UNKNOWN	Influence of Immune Nutrition Diet on 90-Day Outcomes in Patients Undergoing Radical Cystectomy
NCT03147599	PHASE4	COMPLETED	Mebeverine For 1st Year Daytime And Nocturnal Incontinence After Orthotopic W-Ileal Neobladders
NCT03174912	PHASE4	COMPLETED	In the Prediction of Recurrence and Progression of NMIBC; EORTC or CUETO or Both?
NCT03274284	PHASE4	UNKNOWN	Chemoradiotherapy for Recurrent T1G3 Bladder Cancer
NCT03348969	PHASE4	COMPLETED	Neoadjuvant Short-term Intensive Chemoresection Versus Standard Adjuvant Intravesical Instillations in NMIBC
NCT03790384	PHASE4	UNKNOWN	Sequential Combination Therapy in Bladder Cancer
NCT03831321	PHASE4	UNKNOWN	The Effect of Preemptive Analgesia On The Comfort Of Patient and Doctor, in Cystoscopy
NCT05488353	PHASE4	UNKNOWN	A Clinical Study of Disitamab Vedotin for Injection Combined With Penpulimab Injection in Neoadjuvant Therapy for Patients With HER2-expressing Cisplatin-intolerant cT2-T4aNxM0 Bladder Urothelial Carcinoma
NCT06390111	PHASE4	WITHDRAWN	A Trial to Evaluate Efficacy of Reinduction With Nadofaragene Firadenovec in Subjects With CIS ± High-grade Ta/T1 and no Complete Response to First Nadofaragene Firadenovec Dose.
NCT02951325	PHASE3	ACTIVE_NOT_RECRUITING	Bladder Cancer Adjuvant Radiotherapy Trial
NCT03022825	PHASE2/PHASE3	ACTIVE_NOT_RECRUITING	QUILT-3.032: A Multicenter Clinical Trial of Intravesical Bacillus Calmette-Guerin (BCG) in Combination With ALT-803 (N-803) in Patients With BCG Unresponsive High Grade Non-Muscle Invasive Bladder Cancer
NCT03216525	PHASE3	RECRUITING	Alvimopan Versus Placebo in Patients Undergoing Radical Cystectomy on an Enhanced Recovery Protocol
NCT03775265	PHASE3	ACTIVE_NOT_RECRUITING	Chemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder Cancer
NCT03799835	PHASE3	ACTIVE_NOT_RECRUITING	Atezolizumab Plus One-year BCG Bladder Instillation in BCG-naive High-risk Non-muscle Invasive Bladder Cancer Patients
NCT04574960	PHASE3	RECRUITING	Neoadjuvant Upper Tract Invasive Cancer Trial (NAUTICAL)
NCT04579224	PHASE3	ACTIVE_NOT_RECRUITING	Comparing the New Anti-cancer Drug Eribulin With Chemotherapy Against the Usual Chemotherapy Alone in Metastatic Urothelial Cancer
NCT04947059	PHASE3	RECRUITING	Effectiveness of an Immediate Postoperative Intravesical Instillation With Either Gemcitabine or Epirubicin in Patients With Urinary Bladder Cancer (Gemcitabine Epirubicin Normal SAline)
NCT05037279	PHASE3	RECRUITING	Evaluating Safety and Efficacy of Verity-BCG in BCG-naïve Patients With Intermediate and High-risk Non-muscle Invasive Bladder (NMIBC)
NCT05092958	PHASE3	ACTIVE_NOT_RECRUITING	Testing the Addition of the Anti-cancer Drug, Cabozantinib, to the Usual Immunotherapy Treatment, Avelumab, in Patients With Metastatic Urothelial Cancer, MAIN-CAV Study
NCT05243550	PHASE3	ACTIVE_NOT_RECRUITING	A Phase 3 Single-Arm Study of UGN-102 for Treatment of Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer
NCT05704244	PHASE3	ACTIVE_NOT_RECRUITING	Safety and Efficacy of FE 999326 Administered Intravesically to Japanese Subjects With High-grade, BCG Unresponsive, Non-muscle Invasive Bladder Cancer (NMIBC)
NCT05714202	PHASE3	ACTIVE_NOT_RECRUITING	A Study of TAR-200 in Combination With Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants With BCG-naïve High-risk Non-muscle Invasive Bladder Cancer (HR-NMIBC)
NCT05726786	PHASE3	RECRUITING	The Role of Preoperative Immunonutrition on Morbidity and Immune Response After Cystectomy (INCyst Trial)
NCT05810623	PHASE3	NOT_YET_RECRUITING	Single-Dose Intravesical Chemotherapy After Diagnostic URS
NCT06111235	PHASE3	ACTIVE_NOT_RECRUITING	A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT
NCT06331299	PHASE3	ACTIVE_NOT_RECRUITING	A Phase 3 Study of UGN-103 for Treatment of Patients With Low-grade Intermediate-risk Non-muscle Invasive Bladder Cancer
NCT06364904	PHASE3	NOT_YET_RECRUITING	A Clinical Trail to Determine the Safety and Efficacy of the Combination of Tislelizumab With Cisplatin and Gemcitabine, With or Without Trilaciclib for Patients With Untreated Unresectable and Metastatic Urothelial Carcinoma.
NCT06525571	PHASE3	RECRUITING	Outcomes of High-risk Non-muscle Invasive Bladder Cancer Treated With Blue Light Resection
NCT06703476	PHASE3	RECRUITING	A Study of Surgical Techniques During Cystectomy
NCT06851663	PHASE2/PHASE3	RECRUITING	Trop2-targeted immunoPET Imaging of Solid Tumors
NCT07000084	PHASE3	RECRUITING	Testing the Addition of an Anti-Cancer Drug, Gemcitabine, to Usual Treatment (BCG Alone) in People Whose Non-Muscle Invasive Bladder Cancer (NMIBC) Came Back After Prior BCG Therapy

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
MITOMYCIN	4	18
FLUOROURACIL	4	17
SUNITINIB	4	17
VINBLASTINE	4	15
ENFORTUMAB VEDOTIN	4	14
GEMCITABINE	4	14
HEXAMINOLEVULINATE	4	12
CABOZANTINIB	4	9
VINFLUNINE	4	9
PAZOPANIB	4	6
SACITUZUMAB GOVITECAN	4	4
VALRUBICIN	4	4
ATEZOLIZUMAB	4	3
CARBOPLATIN	4	3
ERIBULIN MESYLATE	4	3
NICOTINE	4	3
PACLITAXEL	4	3
SORAFENIB TOSYLATE	4	3
ALVIMOPAN	4	2
AMIFOSTINE	4	2
AVELUMAB	4	2
CISPLATIN	4	2
DICLOFENAC SODIUM	4	2
DOXORUBICIN HYDROCHLORIDE	4	2
FILGRASTIM	4	2
FLUDEOXYGLUCOSE F 18	4	2
GEFITINIB	4	2
NIACINAMIDE	4	2
PEMBROLIZUMAB	4	2
ROMIDEPSIN	4	2